LIDOCAINE HYDROCHLORIDE INJECTION USP SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

LIDOCAINE HYDROCHLORIDE

Tilgjengelig fra:

PFIZER CANADA ULC

ATC-kode:

N01BB02

INN (International Name):

LIDOCAINE

Dosering :

20MG

Legemiddelform:

SOLUTION

Sammensetning:

LIDOCAINE HYDROCHLORIDE 20MG

Administreringsrute:

BLOCK/INFILTRATION

Enheter i pakken:

5ML/20ML/50ML

Resept typen:

Ethical

Terapeutisk område:

LOCAL ANESTHETICS

Produkt oppsummering:

Active ingredient group (AIG) number: 0101280001; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2019-07-02

Preparatomtale

Prescribing Information - Lidocaine Hydrochloride Injection USP_ _
Page 1 of 30
PRESCRIBING INFORMATION
LIDOCAINE HYDROCHLORIDE INJECTION USP
10 mg/mL, 20 mg/mL
Sterile Solution
LOCAL ANESTHETIC
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of
Revision:
July 2,
2019
Submission Control No: 222456
Prescribing Information - Lidocaine Hydrochloride Injection USP_ _
Page 2 of 30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
..........................................................................
3
CONTRAINDICATIONS
................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
4
ADVERSE REACTIONS
...............................................................................................
11
DRUG INTERACTIONS
...............................................................................................
12
DOSAGE AND ADMINISTRATION
..........................................................................
15
OVERDOSAGE
..............................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
....................................................... 22
STORAGE AND
STABILITY.......................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
................................................................... 24
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................... 24
PART II: SCIENTIFIC INFORMATION
............................................................................
26
PHARMACEUTICAL INFORMATION
.....................................................................
26
REFERENCES
........................